Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis


DOI
10.1136/ard.2004.030452

Publication date
2005

Published in
Annals of the Rheumatic Diseases

Citation for published version (APA):
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

G J Wolbink, A E Voskuyl, W F Lems, E de Groot, M T Nurmohamed, P P Tak, B A C Dijkmans and L Aarden


Updated information and services can be found at:
http://ard.bmj.com/cgi/content/full/64/5/704

These include:

References
This article cites 10 articles, 4 of which can be accessed free at:
http://ard.bmj.com/cgi/content/full/64/5/704#BIBL

4 online articles that cite this article can be accessed at:
http://ard.bmj.com/cgi/content/full/64/5/704#otherarticles

Rapid responses
You can respond to this article at:
http://ard.bmj.com/cgi/eletter-submit/64/5/704

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

Drugs: musculoskeletal and joint diseases (345 articles)
Rheumatoid Arthritis (921 articles)

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to Annals of the Rheumatic Diseases go to:
http://www.bmjjournals.com/subscriptions/
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis


Objective: To investigate the relationship between serum trough infliximab levels and clinical response to infliximab treatment in patients with rheumatoid arthritis (RA).

Methods: Disease activity and serum trough infliximab levels before and 2, 6, and 14 weeks after initiation of infliximab treatment at a dose of 3 mg/kg in a cohort of 105 patients with RA were assessed. Serum trough infliximab levels in responders and non-responders were compared. Additionally, the clinical responses of patients with high, intermediate, and low serum trough infliximab levels at 14 weeks were compared.

Results: After 14 weeks of treatment non-responders had lower serum trough levels of infliximab than responders (median (interquartile range) 0.5 (0.2–2.2) vs 3.6 (1.4–8.2) mg/l; p<0.01)). Patients with low serum trough infliximab levels at 14 weeks had significantly less improvement in the 28 joint count Disease Activity Score (DAS28) score than patients with intermediate or high serum trough infliximab levels at 14 weeks. Pretreatment C reactive protein (CRP) levels correlated negatively with serum trough infliximab levels at 14 weeks after the start of treatment (Spearman rank correlation r = –0.43, p<0.001).

Conclusion: Serum trough levels of infliximab correlate with the clinical response to treatment with infliximab and pretreatment CRP levels. This study indicates that patients with high pretreatment CRP levels might benefit from higher dosages of infliximab or shorter dosing intervals.

The efficacy of infliximab as a treatment for patients with active rheumatoid arthritis (RA) has been demonstrated in randomised controlled trials. Currently many patients with active RA despite methotrexate (MTX) treatment receive a standard regimen of infliximab that consists of a 3 mg/kg infusion at 0, 2, and 6 weeks and every 8 weeks thereafter. However, despite treatment with infliximab, many patients have persistent disease activity and some patients do not even reach response criteria. It might be suggested that in such patients tumor necrosis factor (TNF) is not completely neutralised owing to insufficient dosing with infliximab.

The optimal dosing regimen for infliximab is still unknown. A comparison of response rates across infliximab treatment groups in the ATTRACT study indicated a dose-response relationship. Moreover, post hoc analysis of data from the ATTRACT study provided evidence for a significant relationship between the extent of clinical improvement and trough serum concentrations of infliximab. Two recent studies showed that intensification of treatment in non-responders may lead to a significant decrease in the mean Disease Activity Score (DAS). A better understanding of the relationship between disease activity and serum infliximab levels may lead to more effective use of this treatment.

Therefore, we developed an assay for the detection of infliximab in sera and used this to analyse the relationship between clinical improvement and serum trough infliximab levels in patients with RA after 14 weeks of treatment with the standard regimen of 3 mg/kg.

PATIENTS AND METHODS

Patients

One hundred and five consecutive patients with RA receiving infliximab treatment were included in this open, prospective, observational study. Patients were enrolled at the departments of rheumatology of the Slotervaart Hospital and the VU Medical Centre in Amsterdam from April 2000 to January 2002. Patients were included according to the consensus statement on the initiation and continuation of TNF blocking treatments in RA. All patients fulfilled the American College of Rheumatology 2002 revised criteria for RA and all had evidence of active disease, as indicated by a Disease Activity Score in 28 joints (DAS28) of >3.2 despite earlier MTX treatment at a dose of 25 mg weekly or at the maximum tolerable dose.

All patients were given intravenous infusions of 3 mg/kg of infliximab at weeks 0, 2, 6, and 14. Concomitant stable drug treatment, including MTX treatment, was continued. Disease activity was assessed before each infusion (at weeks 0, 2, 6, and 14) using the DAS28 score. In addition, serum samples were collected before each infusion for the assessment of serum infliximab levels and serum C reactive protein (CRP) concentration.

Measurement of serum infliximab levels

Infliximab levels were determined by enzyme linked immunosorbent assay (ELISA). Briefly, a mouse monoclonal antibody directed against TNF (CLB TNF/7) was coated overnight at room temperature (2 μg/ml in 100 μl well) on flat bottomed microtitre plates. Recombinant TNF

Abbreviations: CRP, C reactive protein; DAS28, 28 joint Disease Activity Score; ELISA, enzyme linked immunosorbent assay; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; TNF, tumour necrosis factor
(0.1 μg/ml in a 100 μl well) in HPE buffer (CLB BIR, Amsterdam, The Netherlands) was added for 1 hour. After washing with phosphate buffered saline/0.2% Tween, patients’ serum samples were added in different dilutions in high performance ELISA (HPE) buffer and incubated for 2 hours at room temperature. Plates were washed with phosphate buffered saline/0.2% Tween, then incubated with horseradish peroxidase conjugated monoclonal anti human IgG (MH16) in 100 μl HPE buffer for 1 hour at room temperature. Subsequently, after washing, tetramethylbenzidine was added. The reaction was stopped with 2 M H₂SO₄. Absorption at 450 nm was then determined in a multiscan (Multiskan; Titertek, Elfab Oy, Finland). Results were related to a titration curve of infliximab in each plate. The lowest level of detection was 0.2 mg/l. Figure 1 shows a dose-response curve. The ELISA thus captures infliximab through its ability to bind to TNFα. It does not bind immune complexes consisting of infliximab and TNF or infliximab bound by neutralising antibodies.

Serum CRP levels were assessed by immunonephelometry and used as an indirect marker for TNF production.

Figure 1 Standard curve of infliximab in the ELISA.

Statistical analysis
Patients were classified as responders/non-responders at 14 weeks according to the EULAR response criteria. Non-response was defined as a DAS28 decrease after 14 weeks of ≤0.6, or a decrease >0.6 and ≤1.2 with an attained DAS of >5.1.

The relationship between serum infliximab levels and clinical response was further analysed by categorising patients into tertiles according to their pretreatment CRP level. The relationship of pretreatment CRP levels and clinical response was further analysed by categorising patients into tertiles according to their infliximab level at 14 weeks. Clinical response and serum trough infliximab remained significant after correction for potential confounders such as baseline CRP, baseline DAS28 score, and rheumatoid factor (data not shown).

To analyse further the relationship between serum infliximab levels and clinical response, patients were categorised into three groups according to their infliximab level at 14 weeks. Table 1 shows the results obtained. Patients categorised as having low serum trough infliximab levels at 14 weeks less often fulfilled the EULAR response criteria (50% vs 90% and 88%) and had significantly less improvement in the DAS28 score between 1 and 14 weeks (−0.9 vs −2.0).

Different groups were compared by the Mann-Whitney test or a two-sided Kruskal-Wallis non-parametric test. The Spearman rank test was used for correlations between variables. The threshold for significance was set at p<0.05.

RESULTS
Baseline characteristics of patients
The majority of patients who entered the study were women (82%), with a mean (SD) age of 56 (13) years, and a mean (SD) disease duration of 12 (9) years. Seventy per cent of the patients had tested positive for rheumatoid factor. The mean number of disease modifying antirheumatic drugs used before infliximab treatment was 3.7. Eighty six patients used concomitant methotrexate with a mean dosage of 14 mg every week. At study entry patients had active disease despite MTX treatment, as indicated by a mean (SD) DAS28 score of 6.1 (1.3). (Mean (SD) erythrocyte sedimentation rate (ESR) 40 (25), mean (SD) general health 65 (20), mean (SD) swollen joint count 13 (6), mean (SD) tender joint count 13 (8)).

Figure 2 Serum trough infliximab levels in patients with RA treated with infliximab according to clinical response at 14 weeks.

Clinical response
After 14 weeks of treatment the mean DAS28 score improved from 6.1 to 4.3. Seventy seven (73%) patients fulfilled the EULAR response criteria.

Serum infliximab levels
After 2 weeks the median (interquartile range) serum trough infliximab level was 22.3 (15.3–29.4) mg/l, after a 4 week interval 14.6 (7.3–22) mg/l, and after 8 weeks 2.8 (0.6–6.8) mg/l. Serum trough infliximab levels showed considerable variation between patients (fig 2). Remarkably, serum infliximab levels were below the detection limit in the three serum samples that were collected before all three infusions that induced an allergic reaction.

After 14 weeks of treatment responders had significantly (p<0.01) higher median serum trough infliximab concentrations than non-responders (3.6 (1.4–8.2) vs 0.5 (0.2–2.2) mg/l; fig 3). With multivariate regression analysis the association between clinical response and serum trough infliximab levels at 14 weeks was confirmed. The association between clinical response and serum trough infliximab remained significant after correction for potential confounders such as baseline CRP, baseline DAS28 score, and rheumatoid factor (data not shown).

To analyse further the relationship between serum infliximab levels and clinical response, patients were categorised into three groups according to their infliximab level at 14 weeks. Table 1 shows the results obtained. Patients categorised as having low serum trough infliximab levels at 14 weeks less often fulfilled the EULAR response criteria (50% vs 90% and 88%) and had significantly less improvement in the DAS28 score between 1 and 14 weeks (−0.9 vs −2.0).

www.annrheumdis.com
and −2.4) than patients categorised as having intermediate or high serum trough infliximab levels. During the shorter dosing intervals the improvement of all three groups of patients was similar. However, during the 8 week dosing interval patients with low serum trough infliximab levels at 14 weeks had an increase in mean disease activity while patients with intermediate and high serum trough infliximab levels at 14 weeks showed further improvement in mean DAS28 score (±0.9 v ±0.1 and ±0.2).

**Pretreatment CRP levels, serum infliximab levels, and clinical improvement**

CRP levels before treatment were used as an indirect marker for TNF production. Pretreatment CRP levels negatively correlated with serum infliximab levels at 2 weeks ($r = −0.34$, $p<0.001$), 6 weeks ($r = −0.46$, $p<0.001$), and 14 weeks ($r = −0.43$, $p<0.001$) (fig 4). To investigate the relationship between pretreatment CRP levels and clinical response we categorised patients into three groups according to their pretreatment CRP level and compared the improvement in DAS28 score from 0 to 14 weeks. Moreover the number of EULAR responders was the same for all three groups. During the 8 week treatment interval, however, the change in the DAS28 score of patients with low pretreatment CRP levels significantly differed from that of patients with high pretreatment CRP values (±0.2 (0.6) v 0.6 (1.3), $p = 0.01$). This was seen for all individual factors which comprise the DAS28 (table 2).

**DISCUSSION**

We developed an assay for the detection of infliximab in the serum samples of patients and used this ELISA to investigate the relationship between serum trough infliximab levels and clinical response in a large cohort of patients with RA treated with the standard regimen of 3 mg/kg infliximab. We show that serum trough levels of infliximab after 14 weeks of treatment according to this regimen are higher in responders than in non-responders. In addition, patients with low serum trough infliximab levels have less improvement in the DAS28 score. Interestingly, we also observed a correlation between pretreatment CRP and serum infliximab levels and found that serum infliximab was undetectable before infliximab infusions that induce an allergic response.

![Figure 4](https://www.annrheumdis.com)  
**Figure 4** Correlation between serum trough infliximab levels at 14 weeks and CRP values before treatment in patients with RA treated with infliximab.

### Table 1  Clinical response of patients with low, intermediate, and high serum trough infliximab levels at 14 weeks

<table>
<thead>
<tr>
<th>Clinical response</th>
<th>Serum trough infliximab levels at 14 weeks</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low (0–1.2 mg/l)</td>
<td>Intermediate (1.3–4.7 mg/l)</td>
</tr>
<tr>
<td>Mean DAS28, t=0</td>
<td>6.4</td>
<td>6.1</td>
</tr>
<tr>
<td>Mean CRP, t=0</td>
<td>49</td>
<td>29</td>
</tr>
<tr>
<td>EULAR responders (%)</td>
<td>50</td>
<td>90</td>
</tr>
<tr>
<td>Mean change in DAS28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–2 Weeks</td>
<td>−1.3</td>
<td>−1.2</td>
</tr>
<tr>
<td>2–6 Weeks</td>
<td>−0.4</td>
<td>−0.7</td>
</tr>
<tr>
<td>6–14 Weeks</td>
<td>0.9</td>
<td>−0.1</td>
</tr>
<tr>
<td>0–14 Weeks</td>
<td>−0.9 (−1.4)</td>
<td>−2.0 (−1.3)</td>
</tr>
</tbody>
</table>

*Indicates statistical significance, NS indicates no statistical significance.

### Table 2  Clinical response of patients with low, intermediate, and high pretreatment CRP levels

<table>
<thead>
<tr>
<th>Clinical response</th>
<th>Pretreatment CRP levels</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low (0–10 mg/l)</td>
<td>Intermediate (11–40 mg/l)</td>
</tr>
<tr>
<td>Mean DAS28, t=0</td>
<td>5.3</td>
<td>6.2</td>
</tr>
<tr>
<td>Mean CRP, t=0</td>
<td>4</td>
<td>23</td>
</tr>
<tr>
<td>EULAR responders (%)</td>
<td>74</td>
<td>74</td>
</tr>
<tr>
<td>Mean change in DAS28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–14 Weeks</td>
<td>−1.6</td>
<td>−2.0</td>
</tr>
<tr>
<td>0–2 Weeks</td>
<td>−0.9</td>
<td>−1.3</td>
</tr>
<tr>
<td>2–6 Weeks</td>
<td>−0.5</td>
<td>−0.9</td>
</tr>
<tr>
<td>6–14 Weeks</td>
<td>−0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Mean change in ESR (mm/1st h) 6–14 weeks</td>
<td>−1</td>
<td>4</td>
</tr>
<tr>
<td>Mean change in GH (mm) 6–14 weeks</td>
<td>−5</td>
<td>5</td>
</tr>
<tr>
<td>Mean change in SJC 6–14 weeks</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Mean change in TJC 6–14 weeks</td>
<td>−1</td>
<td>0</td>
</tr>
</tbody>
</table>

*Indicates statistical significance, NS indicates no statistical significance.

GH, general health; SJC, swollen joint count; TJC, tender joint count.
Based on the results of the ATTRACT study most patients with RA are treated with 3 mg/kg of infliximab every 8 weeks. In clinical practice many patients treated with infliximab do not reach clinical remission. Many of these patients are treated with higher dosages of infliximab. Of interest, the ATTRACT study shows a tendency for the lower doses to be less effective than the higher doses. A post hoc analysis of this study suggested a relationship between clinical response and serum infliximab levels. Two recent studies showed an effect of dose escalation in patients with insufficient response. This effect was, however, only limited and might be explained by regression to the mean. Our study confirms the relationship between clinical response and serum through infliximab levels as shown by St Clair et al and extends these observations. As infliximab is expensive it might be efficient to adjust the infliximab dosing schedule after measurement of the serum infliximab concentration.

We used pretreatment CRP levels as an indirect marker of TNF production. We observed a correlation between pretreatment CRP levels, serum trough infliximab levels, and clinical response. Higher levels of TNF production in patients with high CRP levels might explain this relationship. Furthermore, it is possible that infliximab-TNF complexes are cleared from the circulation at a faster rate than unbound infliximab. The clinical implication of this finding is that patients with high pretreatment CRP levels might benefit more from higher dosages of infliximab than patients with low pretreatment CRP levels.

The chimerical antibody infliximab may induce infusion related allergic reactions, which are associated with the formation of anti-infliximab antibodies. In all three patients with a clinically overt infusion reaction serum concentrations of infliximab before the infusion that elicited the reaction were below the detection limit of our assay. This could be due to the binding of infliximab by immune complexes or by anti-infliximab antibodies.

Despite treatment with infliximab infusions many patients with RA still have persistent disease activity. The response to infliximab treatment is related to serum infliximab levels and shows a large variation between patients. Further investigation into the mechanisms that determine serum concentrations of infliximab may help to optimise this treatment.

References